SIO_812200-22_AM_BannerUpdates_728x90.jpg

SIO2022 Annual Scientific Meeting Program

SIO is excited to reconnect in person in San Francisco for the SIO2022 Annual Scientific Meeting. New this year, SIO is offering a Technology Pass to individuals who are unable to attend the in-person meeting. The Technology Pass offers remote attendees access to all live-streamed sessions during the meeting. All plenary and breakout sessions on Friday-Monday will be live streamed. Click here to learn more and register for the Technology Pass.

All Levels
100 Level 
200 Level
300 Level

* denotes in-person faculty, ^ denotes virtual faculty

The session information listed here is subject to change. This page was last updated 28 March 2022. 

Thursday, 24 March 2022

Time (PST)

Session Title

7:00am - 6:30pm

Click here to view IO Essentials Programming.

1:00pm - 2:00pm

*TARE Master Class Part 1: Radiation Physics and Pre-procedure Work-up

Location: Yosemite

Moderator: Daniel Sze*, MD, PhD, Stanford University, USA

  • Y90 Radiation Physics and Cancer Biology, Andrew Kennedy^, MD, FACRO, Sarah Cannon, USA
  • Patient Selection and Clinical Evaluation: HCC, R. Peter Lokken*, MD, MPH, FSIR, UCSF, USA
  • Patient Selection and Clinical Evaluation: Metastatic Disease, David Mauro^, MD, University of North Carolina, USA
  • Mapping Angiography, Protective Embolization, Anti-reflux Catheters, and Cone Beam CT, Daniel Sze*, MD, PhD, Stanford University, USA
  • Tc-99m MAA Shunt Study: Determining Tumor to Normal Liver Perfusion Ratio, S. Cheenu Kappadath*, PhD, UT MD Anderson Cancer Center, USA: 
  • Strategies for High Lung Shunt Fraction, John Louie*, MD, Stanford University, USA
2:00pm - 2:30pm

Hands-on Equipment Showcase

Location: Yosemite

2:30pm - 3:30pm

*TARE Master Class Part 2: TARE for HCC

Location: Yosemite

Moderator: Siddharth Padia*, MD, UCLA, USA

  • Product Selection: Y90 Glass vs. Resin, Daniel Sze*, MD, PhD, Stanford University, USA
  • Holmium 166 Primer for Non-users, Marnix Lam*, MD, PhD, University Medical Center Utrecht, Netherlands
  • HCC Applications and Dosimetry: Radiation Segmentectomy, Siddharth Padia*, MD, UCLA, USA 
  • HCC Applications and Dosimetry: Radiation Lobectomy, Robert Lewandowski^, MD, FSIR, Northwestern Medicine, USA
  • HCC Applications and Dosimetry: Macrovascular Invasion, Beau Toskich^, MD, Mayo Clinic, USA
  • HCC Applications and Dosimetry: Multifocal Disease, Suvranu Ganguli*, MD, Boston Medical Center/Boston University of Medicine, USA
3:30pm - 4:00pm

Hands-on Equipment Showcase

Location: Yosemite

4:00pm - 5:00pm 

*TARE Master Class Part 3: TARE for Liver Metastases

Location: Yosemite

Moderator: Suvranu Ganguli*, MD, Boston Medical Center/Boston University of Medicine, USA

  • Metastatic Disease: Y90 Treatment Strategies, Ed Boas*, MD, PhD, City of Hope Cancer Center, USA
  • Y90 Resin Dosimetry: Optimization of Tumor and Liver Parenchyma Dose, S. Cheenu Kappadath*, PhD, UT MD Anderson Cancer Center, USA
  • Same Day Mapping and Treatment, Riad Salem*, MD, MBA, Northwestern University, USA
  • Radiation SensitizersNicholas Fidelman*, MD, UCSF, USA
  • Mitigation of Radioembolization Risks, Amy Deipolyi^, MD, PhD, West Virginia University, USA
5:30pm - 6:30pm

*TARE Master Class Part 4: M&M

Location: Yosemite

Moderator: Riad Salem*, MD, MBA, Northwestern University, USA 

  • M&M Save, Susan Shamimi-Noor,* MD, University of Pennsylvania, USA
  • M&M Disaster, Beau Toskich^, MD, Mayo Clinic, USA
  • M&M Save, Michael Heller^, MD, UCSF, USA
  • M&M DisasterSuvranu Ganguli*, MD, Boston Medical Center/Boston University of Medicine, USA
  • M&M Save, Siddharth Padia*, MD, UCLA, USA
  • Q&A, All faculty

*An additional fee is required to attend the TARE Master Class.

Friday, 25 March 2022

Time (PST)

Session Title(s)

7:45am - 9:00am 

Welcome and Dr. Sidney Wallace and Dr. Michael J. Wallace Distinguished Lecture

Location: Grand Ballroom A

Laudation provided by Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania

Riad Salem*, MD, MBA, Northwestern University, USA

9:00am - 10:30am

HCC

Location: Grand Ballroom A

Moderators: Isabel Newton*, MD, PhD, VA San Diego Healthcare System and UC San Diego, USA; Sarah White*, Medical College of Wisconsin, USA

  • LIRADS: Therapeutic Response, Yuko Kono^, MD, PhD, UCSD, USA
  • Harnessing Tumor Metabolism to Overcome Loco-regional Therapy Failures, Terence Gade^, MD, PhD, Penn Image-Guided Interventions Lab, University of Pennsylvania, USA
  • Compete or Combine: Lessons from the Imbrave-150 Trial, Riccardo Lencioni^, MD, University of Pisa School of Medicine, Italy
  • Beyond the Algorithm: How to Choose the Best LRT, Nadine Abi Jaoudeh*, MD, FSIR, CCRP, University of California Irvine, USA
  • Evolution of Radioembolization in HCC: Big Doses, Small PlacesRobert Lewandowski^, MD, FSIR, Northwestern Medicine, USA
  • Latest Trends in Ablation, Laura Crocetti*, Prof., MD, PhD, University of Pisa School of Medicine, Italy
  • Changing Landscape of Systemic Therapies for HCC, John Gordan*, MD, UCSF, USA
10:30am - 10:40am

Ethics of Consent in IR

Location: Grand Ballroom A

Presented in partnership with The Interventional Initiative

  • Patient Decision Aids to Improve Patient Care in IO, Eric Keller*, MD, MA, Stanford University, USA

11:00am - 12:00pm

Complex Cases

Location: Grand Ballroom A

Moderators: Edward Kim*, MD, Mount Sinai Health Systems, USA; Matthew Callstrom*, MD, PhD, Mayo Clinic, USA; Stephen Solomon*, MD, Memorial Sloan Kettering Cancer Center, USA

Moderators will bring cases for discussion.

Pain Palliation

Location: Imperial AB

Moderators: Sean Tutton*, MD, FSIR, FCIRSE, UCSD, USA; Dimitrios Filippiadis*, University of Athens, Greece

  • Pharmacological Management of Cancer Pain in 2022, Paul Lindenfeld^, MD, UCSF, USA
  • Nerve Blocks and Steroid Injections for Cancer Pain, Dan Nguyen^, MD, Neuroradiology & Pain Solutions of Oklahoma, USA
  • Percutaneous Neurolysis in 2022: Facing the Challenges, J. David Prologo*, MD, FSIR, ABOM-D, Emory University School of Medicine, USA
  • The Role of Percutaneous Ablation in the Palliation of Cancer Pain, Alan Sag*, MD, Duke University Medical Center, USA
  • Multidisciplinary Approach to Cancer Pain with Combination Treatment, Sean Tutton*, MD, FSIR, FCIRSE, UCSD, USA
12:30pm - 1:15pm

Industry Symposium

IO Clinical Trials: Essential Recent Data for the IR

Location: Imperial AB

Presented by Boston Scientific Corporation

  • Scott J. Genshaft*, MD, UCLA, USA
  • Robert Lewandowski*, MD, FSIR, Northwestern Medicine, USA
1:25pm - 2:10pm

Industry Symposium

Interventional Immunotherapy: Transforming the Treatment of Solid Tumors

Location: Imperial AB

Presented by TriSalus Life Sciences®

  • Alex Kim*, MD, Medical Director at National Vascular Physicians
  • Steven C. Katz*, MD, FACS, Chief Medical Officer at TriSalus Life Sciences®
  • Rahul Sheth*, MD, Associate Professor of Interventional Radiology at MD Anderson Cancer Center
2:20pm - 3:50pm

Controversies

Location: Grand Ballroom A

ModeratorsDavid Breen*, MD, University Hospital Southampton, UK; William Rilling*, MD, FSIR, Medical College Wisconsin, USA

  • Painful Pelvic Metastasis: Radiotherapy or Ablation?, A. Nick Kurup*, MD, Associate Professor of Radiology, Mayo Clinic, USA v. Mary Feng*, MD, UCSF, USA
  • PVE vs. Double Venous Deprivation: Why?, Daniel Brown^, MD, Vanderbilt University Medical Center, USA v. Alban Denys^, Pr. CHUV University of Lausanne, USA
  • Peripheral Colorectal Lung Mets: SBRT vs. Ablation, Thierry de Baere*, MD, Gustave Roussy, France v. Abraham Wu^, MD, Memorial Sloan Kettering Cancer Center, USA
  • Intermediate HCC: The Shifting TACE and Systemic Therapy Interface, Robert Lewandowski*, MD, FSIR, Northwestern Medicine, USA, v. Laura Crocetti*, Prof., MD, PhD, University of Pisa School of Medicine, Italy
4:00pm - 5:00pm

HCC Tumor Board

Location: Grand Ballroom A

Moderators: Robert Lewandowski*, MD, FSIR, Northwestern Medicine, USA; Isabel Newton*, MD, PhD, VA San Diego Healthcare System and UC San Diego, USA; David Breen*, MD, University Hospital Southampton, UK  

Case Discussions:

  • John Gordan*, MD, UCSF, USA
  • Cristal Brown*, MD, MHS, University of Texas at Austin Dell Medical School, USA
  • Mary Feng*, MD, UCSF, USA
  • Nadine Abi Jaoudeh*, MD, FSIR, CCRP, University of California Irvine, USA
  • Laura Crocetti*, Prof., MD, PhD, University of Pisa School of Medicine, Italy
  • Garrett Roll*, MD, FACS, UCSF, USA
  • Nishita Kothary*, MBBS, FSIR, Stanford University, USA
5:15pm - 6:15pm

Scientific Oral Abstract Presentations

Location: Grand Ballroom A

ModeratorsDamian Dupuy*, MD, FACR, Cape Cod Hospital, USA; Dimitrios Filippiadis*, University of Athens, Greece

  • 3D Quantitative Ablation Margins for Prediction of Ablation Site Recurrence After Stereotactic Image-guided Microwave Ablation of Colorectal Liver, Simeon Ruiter^, MSc, University Medical Center Groningen, Netherlands
  • A Randomized, Open-label, International, Multicenter, Phase 3 Trial of Radioembolization with Chemotherapy for Colorectal Liver Metastases: The EPOCHRobert Lewandowski*, MD, FSIR, Northwestern Medicine, USA
  • Y90 Radiation Segmentectomy of HCC: A Comparative Study of Effectiveness, Safety and Dosimetry of Glass vs. Resin-based Microspheres, Alexander Villalobos^, MD, Emory University School of Medicine, USA
  • Lymphatic Embolization vs. Sclerotherapy in Management of Iatrogenic Lymphoceles after Oncological Surgery, Ahmed Aly*, MB, BCh, Memorial Sloan Kettering Cancer Center, USA
  • Characterizing Combined Hepatocellular Cholangiocarcinoma in Patients Who Have Undergone Treatment With Locoregional Therapies, Anusha Naik^, BS, University of Pennsylvania, USA
  • Percutaneous Microwave Ablation for Soft Tissue Retroperitoneal Tumors, Annika Rossebo*, University of Wisconsin - Madison, USA
  • The Role of a Navigational Radiofrequency Ablation Device and Concurrent Vertebral Augmentation for Treatment of Difficult-to-reach Spinal Metastases, Claudio Pusceddu*, MD, Oncological and Interventional Radiology Departement ARNAS, Italy
6:30pm - 7:30pm

Opening/Founding Members Reception

Location: Exhibit Hall, Grand Ballroom B

Saturday, 26 March 2022

Time (PST)

Session Title(s)

7:15am - 8:00am

Industry Symposium

Cryoablation with Liquid Nitrogen for Optimal Tumor Destruction 

Location: Imperial AB

Presented by IceCure Medical

Moderator: Jack Jennings*, MD, Professor of Radiology, Division of Diagnostic Radiology, Section of Musculoskeletal Radiology, Washington University School of Medicine

  • John David Prologo*, MD, Director of Interventional Radiology Services, Emory Johns Creek Hospital, USA

  • Jason Williams*, MD, Adjunct Professor, Case Western Reserve University, Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, USA

8:30am - 9:30am

Immuno Oncology

Location: Grand Ballroom A

Moderators: Muneeb Ahmed*, MD, Beth Israel Deaconess Medical Center/Harvard, USA; Alda Tam*, MD, MD Anderson Cancer Center, USA

  • Immuno Oncology: Checkpoint Inhibitors and Beyond, Antonia Digklia^, MD, MSc, Centre Hospitalier Universitaire Vaudoise CHUV, Switzerland
  • Role of IO in Immuno Oncology, Erica Alexander,^ MD, Memorial Sloan Kettering Cancer Center, USA
  • Manipulating the Tumor Microenvironment, Alda Tam*, MD, MD Anderson Cancer Center, USA
  • Imaging the Immune Response, Jessica Santana*, PhD Student, Yale University, USA
  • Immunoadjuvants: The Role of Percutaneous Delivery, Rahul Sheth*, MD, MD Anderson Cancer Center, USA
9:50am - 10:50am 

Applied Immuno Oncology

Location: Grand Ballroom A

Moderators: Stephen Hunt*, MTR, MD, PhD, University of Pennsylvania, USA; Joseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA

  • Immunomodulation in TACE SettingsStephen Hunt*, MTR, MD, PhD, University of Pennsylvania, USA
  • IRE to Improve Tumor Microenvironments and Checkpoint Sensitivity in Pancreatic Cancer, Jayanth Shankara Narayanan^, PhD, UCSD, USA
  • IA CAR T-cell in Metastatic Colorectal Disease, Gregory Nadolski^, MD, University of Pennsylvania, USA
  • Bench to Bedside: Liver, Muneeb Ahmed*, MD, Beth Israel Deaconess Medical Center/Harvard, USA
  • Q&A, All faculty

Getting Started

Location: Imperial AB

Moderators: David Breen*, MD, University Hospital Southampton, UK; Jack Jennings*, MD, PhD, Washington University, USA

  • IRE, Ronald Arellano*, MD, Massachusetts General Hospital, USA
  • Chemosaturation, Brian Stedman^, Consultant Interventional Radiologist, University Hospital Southampton, UK
  • Injectable Intra-tumoral Treatments, Rahul Sheth*, MD, MD Anderson Cancer Center, USA
  • Cementoplasty, Francois H. Cornelis^, MD, PhD, Memorial Sloan Kettering Cancer Center, USA
  • Problem Lymph Node Ablations, Philippe Pereira^, MD, SLK Kliniken, Germany
  • Thyroid Ablation, Laura Crocetti*, Prof., MD, PhD, University of Pisa School of Medicine, Italy
11:20am - 12:20pm

MSK Mets

Location: Grand Ballroom A

Moderators: Matthew Callstrom*, MD, PhD, Mayo Clinic, USA; Sean Tutton*, MD, FSIR, FCIRSE, UCSD, USA

  • Bone and Soft Tissue Biopsies of Metastatic Disease: Tips and Tricks for the Challenging Cases, Travis Hillen^, MD, Washington University School of Medicine St. Louis, USA
  • Treatment of Pathologic Fractures of the Spine: Vertebral augmentation from cement to implants, Alexis Kelekis*, MD, PhD, EBIR, FCIRSE, FSIR, National and Kapodistrian University of Athens, Greece
  • The Role of Bone Ablation for Local Tumor Control, Lindsay Stratchko^, DO, University of Wisconsin, USA
  • Treatment of Extra-spinal Pathologic Fractures: Percutaneous Osteoplasty from Cement to Screws and Implants, Frederic Deschamps*, MD, PhD, Gustave Roussy, France
  • Complications of Percutaneous Ablation: How to Minimize and Avoid, Matthew Callstrom*, MD, PhD, Mayo Clinic, USA

Pancreaticobiliary

Location: Imperial AB

Moderators: Sarah White*, Medical College of Wisconsin, USA; Rony Avritscher*, University of Texas MD Anderson Cancer Center, USA

  • Advances in Pancreatic Cancer Treatment: A Surgeon's Perspective, Flavio Rocha^, Oregon Health and Science University, USA
  • Local Interventions for Advanced Pancreatic Carcinoma in the Era of Immunotherapy, Martijn Meijerink^, Amsterdam UMC, Netherlands
  • Cholangiocarcinoma: An Overview of Novel Actionable Mutations, Bruno Odisio*, The University of Texas MD Anderson Cancer Center, USA
  • Is TARE Superior to TACE for Unresectable Cholangiocarcinoma: An In-depth Analysis, Christina Mosconi^, IRCCS, Policlinico Sant’orsola Hospital, Italy
  • Palliative Treatment with Radiation-emitting Metallic Stents in Unresectable Hilar Cholangiocarcinoma, Gao-Jun Teng^, Department of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Southeast University, China
12:30pm - 1:15pm

Industry Symposium

Personalized Y90 Dosimetry in Treatment of Colorectal Liver Metastasis: Why is it Important?

Location: Yosemite

Presented by Sirtex Medical

Nima Kokabi*, MD, FRCP, Assistant Professor, Department of Radiology and Imaging Sciences, Emory University School of Medicine

1:25pm - 2:10pm

New Advances in Catheter-directed Therapy

Location: Grand Ballroom A

Moderators: Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA; Nicholas Fidelman*, MD, UCSF, USA

  • Bronchial Artery Chemoembolization, Ed Boas*, City of Hope Cancer Center, USA
  • Embolization for Renal Cell Carcinoma, Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA
  • Embolization of Head and Neck Tumors: Current Status, Kazim Narsinh*, MD, UCSF, USA

2:20pm - 3:50pm

mCRC

Location: Grand Ballroom A

Moderators: Costi Sofocleous*, MD, PhD, Weill-Cornell Medical College/Memorial Sloan Kettering Cancer Center, USA; William Rilling*, MD, FSIR, Medical College Wisconsin, USA; Nicholas Fidelman*, MD, UCSF, USA

  • Actionable Mutations: The Geography of mCRC, Antonia Digklia^, MD, MSc, Centre Hospitalier Universitaire Vaudoise CHUV, Switzerland
  • Vanishing Metastases: Resect, Ablate, Wait?, Martijn Meijerink^, MD, PhD, Amsterdam UMC, Netherlands
  • Is Surgical Wedge Resection Still the Gold Standard?, Eric Nakakura*, MD, UCSF, USA
  • Ablation of mCRC: Effectiveness?, Costi Sofocleous*, MD, PhD, Weill-Cornell Medical College/Memorial Sloan Kettering Cancer Center, USA
  • FLR Assessment: How To, David Madoff^, MD, Yale School of Medicine, USA 
  • Double Venous Deprivation: Really?, Boris Guiu^, MD, PhD, Montpellier University Hospital, France
  • Radioembolization: Current Best Utilization, Daniel Brown^, MD, Vanderbilt University Medical Center, USA
4:00pm - 5:00pm

mCRC Tumor Board

Location: Grand Ballroom A

Moderators: Costi Sofocleous*, MD, PhD, Weill-Cornell Medical College/Memorial Sloan Kettering Cancer Center, USA; William Rilling*, MD, FSIR, Medical College Wisconsin, USA

Case Discussions:

  • Eric Nakakura*, MD, UCSF, USA
  • Nicholas Fidelman*, MD, UCSF, USA
  • Mary Feng*, MD, UCSF, USA
  • Ronald Arellano*, MD, Massachusetts General Hospital, USA
  • Alan Venook, MD, UCSF, USA

SIO Meets KSIR: Current Status of Interventional Treatment of HCC in Korea

Moderators: Chang Won Kim^, KSIR Vice President, Pusan National University, Korea; Uei Pua^, MBBS, Tan Tock Seng Hospital, Singapore; Sarah White*, MD, MS, Medical College of Wisconsin, USA; Alexis Kelekis*, MD, PhD, EBIR, FCIRSE, FSIR, National and Kapodistrian University of Athens, Greece

  • Introduction to KSIRChang Won Kim^, KSIR Vice President, Pusan National University, Korea
  • Chemoembolization, In Joon Lee^, MD, PhD, National Cancer Center, Korea
  • Radioembolization, Hyo-Cheol Kim^, PhD, Seoul National University Hospital, Korea
  • Ablation Therapy, Dong Ho Lee^, MD, MS, Seoul National University Hospital, Korea
5:15pm - 6:15pm

Scientific Oral Abstracts - SIO Debut Presentations

Location: Grand Ballroom A

ModeratorsWilliam Rilling*, MD, FSIR, Medical College Wisconsin, USA; Dimitrios Filippiadis*, University of Athens, Greece

  • Prospective Study on the Immunological Effects of Conventional Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: An interim analysis, Robin Schmidt*, Department of Radiology, Charité Virchow Klinikum, Germany
  • Virtual Platform for Assessing Liver Tumor Ablation Margin: Microwave Ablation vs. Intravascular Plasmonic Photothermal Ablation, Mir Hadi Razeghi Kondelaji^, MSc, Medical College of Wisconsin, USA
  • Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-year Analysis from the Prospective of Amsterdam CORE Registry (AmCORE), Robbert S. Puijk*, MD, Amsterdam University Medical Centers, VU Medical Center Amsterdam
  • Long-term Outcome After Thermal Ablation for Renal Cancer in the Non-elderly, Healthy Population, Wenhui Zhou^, MD, PhD, Stanford University, USA
  • Real-time PET Improves Tumor Detection and Ablation Margin Calculation When Used in Combination with CT-guided Ablation of Colorectal Liver Metastases, Mahdi Zirakchian Zadeh^, MD, Memorial Sloan Kettering, USA
  • Hepatic and Renal Histotripsy in an Anticoagulated Swine Model, Scott Mauch*, MD, University of Wisconsin, USA
  • Percutaneous Vesselplasty in Osteolytic Primary or Secondary Vertebral Lesions After the Radiofrequency Ablation: Safety and Efficacy, Chiara Zini^, MD, PhD, USL Toscana Centro, Italy
6:30pm - 8:00pm

Trivia Night

Location: Imperial AB

Presented by Sirtex Medical

Sunday, 27 March 2022

Time (PST)

Session Title(s)

7:15am - 8:00am

MR Lymphangiography and Lymphatic Interventions

Location: Imperial AB

Maxim Itkin*, MD, Penn Medicine, USA

8:30am - 9:30am

AI

Location: Grand Ballroom A

Moderator: Joseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA;  Bradford Wood*, MD, National Institutes of Health, USA; Lynne Martin*, IR/DR PGY5, Stanford University, USA

  • What is AI?, Krishna Nand Keshavamurthy^, PhD, Memorial Sloan Kettering Cancer Center, USA
  • AI Problems and Direction of Travel, Julius Chapiro^, MD, PhD, Assistant Professor of Radiology and Biomedical Imaging, Interventional Oncology Lab, Yale University School of Medicine, USA
  • Using Deep Learning to Address the Response to Image-guided Intervention, Iwan Paolucci*, PhD, MD Anderson Cancer Center, USA
  • Implementing AI into Your IR Practice, Dania Daye^, MD, PhD, Massachusetts General Hospital/Harvard Medical School, USA
  • Q&A and Discussion, All faculty

Lung

Location: Imperial AB

Moderator: Damian Dupuy*, MD, FACR, Cape Cod Hospital, USA; Robert Suh*, Clinical Professor, Radiological Sciences, David Geffen School of Medicine at UCLA, USA; Thierry de Baere*, MD, Gustave Roussy, France

  • Updates on Lung Cancer Surgery, Jay M. Lee^, MD, Chief Division of Thoracic Surgery, UCLA Health, USA
  • Imaging Evaluation Workup Pre- and Post-ablation, Florian J. Fintelmann^, MD, Massachusetts General Hospital, USA
  • When SBRT and When Not for Lung Tumors?, Andreas Rimner*, Associate Attending, Director of Thoracic Radiation Oncology Research, Memorial Sloan Kettering Cancer Center, USA
  • Current State of Interventional Pulmonology and Early Stage Lung Cancer, Scott Oh^, DO, UCLA, USA
  • Current Guidelines for NSCLC and Oligometastatic Disease to the Lungs, Scott J. Genshaft^, MD, UCLA, USA
  • Combination Approach to Treating Lung Cancer Patients, Damian Dupuy*, MD, FACR, Cape Cod Hospital, USA
9:50am - 10:50am

Midgut mNET with NANETS

Location: Grand Ballroom A

Moderators: Rony Avritscher*, MD, University of Texas MD Anderson Cancer Center, USA; Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA

  • Medical and Surgical Therapy Landscape for Well-differentiated NET Liver Metastases in 2022, Emily Bergsland^, MD, UCSF, USA
  • Peptide Receptor Radionuclide Therapy: A Primer for Interventional Radiologists, Ghassan El-Haddad*, MD, Moffitt Cancer Center and Research Institute, USA
  • Liver-directed Therapy Before and After PRRT, Nicholas Fidelman*, MD, UCSF, USA
  • Radioembolization in the Era of PRRT, Etay Ziv^, MD, PhD, Memorial Sloan Kettering Cancer Center, USA
  • Staying Out of Trouble: Tips for Prevention of Carcinoid Crisis and Other Hormone-mediated Side Effects, Rony Avritscher*, MD, University of Texas MD Anderson Cancer Center, USA

Breaking Ground

Location: Imperial AB

Moderators: Sarah White*, MD, MS, Medical College of Wisconsin, USA; Stephen Solomon*, MD, Memorial Sloan Kettering Cancer Center, USA

  • Pediatric Liver IO, Allison Aguado*, MD, Nemours Children's Hospital, Delaware, USA
  • Breast IO: Where Are We?, Yolanda Bryce^, MD, Memorial Sloan Kettering Cancer Center, USA
  • Initiating MR-guided Programs, David Woodrum^, MD, PhD, Mayo Clinic, USA
11:20am - 12:20pm

MSK Sarcoma

Location: Grand Ballroom A

Moderator: Jack Jennings*, MD, PhD, Washington University, USA; A. Nick Kurup*, MD, Associate Professor of Radiology, Mayo Clinic, USA

  • Combining Systemic and Local Therapy for Sarcoma Metasteses, Brian Schulte*, MD, UCSF, USA
  • Ablation and Other Palliative Techniques for Painful Sarcoma Lesions, Roberto Luigi Cazzato^, Associate Professor, University Hospital of Strasbourg, France
  • Percutaneous Ablation in Oligometastatic MSK Sarcoma for Local Tumor Control, Jack Jennings*, MD, PhD, Washington University, USA
  • Percutaneous Ablation for Desmoids: What is the Evidence?, Afshin Gangi^, MD, University Hospital of Strasbourg, France/King’s College London, UK
  • What is the Role of HIFU for the Treatment of Sarcomas and Desmoids?, Karun Sharma*, MD, PhD, Children's National Hospital & George Washington University, USA

Residents to Experts

Location: Imperial AB

Moderators: Vijay Ramalingam*, MD, Beth Israel Deaconess Medical Center, USA; Evan Lehrman*, MD, FSIR, UCSF, USA; Sarah White, MD, MS, Medical College of Wisconsin, USA; David Breen*, MD, University Hospital Southampton, USA; Eric Keller*, MD, MA, Stanford University, USA

  • Direct RFA of Portal Vein Tumor Thrombus in Continuity with HCC, Ioanna Thanou*, Resident, Sotiria General Hospital of Athens, Greece
  • Two 90Yttrium Radioembolization Cases Complicated by Inconclusive 99mTc-MAA Mapping and Their Subsequent Approaches Colin Marshall*, DO, University of Cleveland Medical Center
  • Embolization of Large Arterio-bronchial Fistula Due to Metastatic Breast Cancer, Jonathon Weber^, MD, University of Kentucky, USA
  • Inoperable Tumor-induced Osteomalacia, Hoowon Lee, MD, National Institutes of Health Intramural Research Program, USA
  • IO for Complex HCC, Lynne Martin*, IR/DR PGY5, Stanford University, USA
12:30pm - 1:15pm

Industry Symposium

The Rebirth of Lymphangiography 

Location: Yosemite

Presented by Guerbet

Maxim Itkin*, MD, Penn Medicine, USA

1:25pm - 2:10pm

Industry Symposium

Histotripsy: The Future of Liver Therapy? The Novel Science of Histotripsy and Procedural Advancements 

Location: Yosemite

Presented by HistoSonics

  • Paul F Laeseke*, MD, PhD, Assistant Professor of Radiology, Vascular and Interventional Radiology, University of Wisconsin School of Medicine and Public Health, USA
  • Fred T. Lee Jr., MD*, Professor of Radiology and Urology, University of Wisconsin, USA

2:20pm - 3:50pm

Optimized TACE Mini Master Class

Location: Grand Ballroom A

Moderators: Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA; Sarah White*, MD, MS, Medical College Wisconsin, USA; Nishita Kothary*, MBBS, FSIR, Stanford University, USA

  • Optimal Preparation and Treatment Endpoints in cTACE, Sarah White*, MD, MS, Medical College Wisconsin, USA
  • Drug Recommendations for TACE, R. Peter Lokken*, MD, MPH, FSIR, UCSF, USA
  • How to Improve Local Tumor Control in Super-selective cTACE, Toshihiro Tanaka^, Nara Medical University, Japan
  • Determining the Ideal Bead Size for EmbolizationJoseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA
  • TACE via Extrahepatic Collaterals: Safety Considerations, Kristen Lee^, MD, Singapore General Hospital, Singapore
  • Hands-on Equipment Showcase, All faculty

Lung Mini Master Class

Location: Imperial AB

Moderators: Robert Suh*, Clinical Professor, Radiological Sciences, David Geffen School of Medicine at UCLA, USA; Damian Dupuy*, MD, FACR, Cape Cod Hospital, USA

  • Complication: Great Saves, Robert Suh*, Clinical Professor, Radiological Sciences, David Geffen School of Medicine at UCLA, USA
  • Complication: Disasters, Fereidoun Abtin*, MD, UCLA Medical Center, USA
  • Biopsy and Ablation: Simultaneous and Sequential Best Techniques, Thierry de Baere^, MD, Gustave Roussy, France
  • Freeze: When, Why, and Where?, Peter John Littrup^, MD, Ascension Providence Rochester Hospital, USA
  • Burn: When, Why, and Where?, Stephen Solomon*, MD, Memorial Sloan Kettering Cancer Center, USA
  • Q&A, All faculty
4:00pm - 5:00pm

"How I Do It" Video Session

Location: Grand Ballroom A

Moderators: Vijay Ramalingam*, MD, Beth Israel Deaconess Medical Center, USA; Steven Yevich*, MD, MPH, University of Texas MD Anderson Cancer Center, USA

  • Complex Pelvic Instrumentation, Frederic Deschamps*, MD, PhD, Gustave Roussy, France
  • Lymphatic Intervention, Gregory Nadolski^, MD, University of Pennsylvania, USA
  • Venous Intervention for Palliation in SVC Syndrome/Lower Extremity EdemaEvan Lehrman*, MD, FSIR, UCSF, USA
  • Complex Renal Cryoablation (T1B > 4 cm), Ryan Michael Kohlbrenner*, MD, UCSF, USA
  • Chemosaturation, Brian Stedman^, Consultant Interventional Radiologist, University Hospital Southampton, UK

Meet the Researchers Forum

Location: Imperial AB

Moderators: Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA; Muneeb Ahmed*, MD, Beth Israel Deaconess Medical Center/Harvard, USA;  Joseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA 

  • RETNET (Neuroendocrine carcinoma, cTACE vs. bland embolization), Michael Soulen*, MD, FSIR, FCIRSE, Abramson Cancer Center, University of Pennsylvania, USA
  • COLLISION Trial (Colorectal ablation vs surgery), Martijn Meijerink^, MD, PhD, Amsterdam UMC, Netherlands
  • COVERALL Trial (Software-aided imaging to increase tumor coverage during ablation), Bruno Odisio*, MD, FSIR, The University of Texas MD Anderson Cancer Center, USA
  • iHEPAR Trial (HCC treatment with individualized approach using holmium-166), Marnix Lam*, MD, PhD, University Medical Center Utrecht, Netherlands
  • EMERALD-1 (HCC treated with TACE + immune checkpoint blockade), Joseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA

5:15pm - 6:30pm

Scientific Oral Abstracts & Awards Presentation

Location: Grand Ballroom A

Moderators: Alexis Kelekis*, MD, PhD, EBIR, FCIRSE, FSIR, National and Kapodistrian University of Athens, Greece; Bradford Wood*, MD, National Institutes of Health, USA

  • Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases: Results from the AmCORE, Madelon Dijkstra^, MD, Amsterdam University Medical Centers, VU Medical Center Amsterdam
  • In Situ Vaccination Approach to Treating HCC by Combining Percutaneous Cryoablation With a Plant Virus Nanoparticle Immunoadjuvant, Mansur Ghani^, MD, University of California, San Diego, USA
  • Evaluation of LIRADS Treatment Response Criteria in Determining HCC Viability Post Locoregional Therapy in Transplant Patients, Ajay C. Makkena^, BS, Thomas Jefferson University, USA
  • Antitumor Efficacy of Transarterial Bland Embolization with Concurrent Everolimus (EveroEmbo) in the Treatment of Hepatic Metastatic Neuroendocrine Tumors, Emad Chishti^, BS, University of Kentucky College of Medicine, USA
  • Incidence of Delayed Local Recurrence and Oncological Survival After Thermal Ablation For Early Stage Renal Cell Cancer: A 10-year outcome analysis, Wenhui Zhou^, MD, PhD, Stanford University, USA
  • Randomized Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma as Bridge to TransplantGregory Nadolski^, MD, University of Pennsylvania, USA
  • Augmented Fluoroscopy Guided Transbronchial Pulmonary Microwave Ablation Obviates the Need for a Bronchoscope, Mario Ghosn^, MD, Memorial Sloan Kettering Cancer Center, USA
6:30pm - 8:30pm

*Social Event - SIO 5 Year Anniversary Celebration

* a separate fee is required to attend the Social Event

The Press Club San Francisco

Monday, 28 March 2022

Time (PST)

Session Title

8:30am - 9:30am

Renal

Location: Imperial A

Moderators: David Breen*, MD, University Hospital Southampton, UK; Vijay Ramalingam*, MD, Beth Israel Deaconess Medical Center, USA

  • Indolent Renal Cell Cancer: When to Resect, Ablate or Wait?, Maxwell Meng*, MD, UCSF, USA
  • Heritable Renal Cancer Syndromes, Joyce So^, MD, PhD, FRCPC, FCCMG, UCSF, USA
  • Ablation of RCC: Current Status, Grant Schmit^, MD, Mayo Clinic, USA
  • Awkward RCC Ablation, Brian Welch^, MD, Mayo Clinic, USA
  • Loco-regional Treatments for Metastatic RCC, Dimitrios Filippiadis*, MD, PhD, MSc, EBIR, University of Athens, Greece
9:30am - 10:30am

Prostate

Location: Imperial A

Moderators: Eric M. Walser*, MD, University of Texas Medical Branch, USA; Vijay Ramalingam*, MD, Beth Israel Deaconess Medical Center, USA

  • Focal Therapy of Prostate: Why, When, How Much?, Dan Sperling^, MD, DABR, Sperling Prostate Center, USA
  • Focal Therapies: MR- vs. US-guided, Eric M. Walser*, MD, University of Texas Medical Branch, USA 
  • Best Energies in Prostate Ablation, David Woodrum^, MD, PhD, Mayo Clinic, USA
  • MR/US Fusion-guided HIFU of Prostate Cancer, Afshin Gangi^, MD, University Hospital of Strasbourg, France/King's College, UK
  • Prostate Cancer Focal Therapy: Today and Tomorrow, Hao Nguyen, MD, PhD*, UCSF, USA
11:00am - 12:00pm

Palliative Care: Multidisciplinary Approach

Location: Imperial A

ModeratorsNicholas Fidelman*, MD, UCSF, USA; Joseph Erinjeri*, MD, PhD, Memorial Sloan Kettering Cancer Center, USA

  • Nerve Blocks for Pain Palliation, Louis-Martin Boucher^, MD, PhD, McGill University, Canada
  • Symptom Management Service, Michael Rabow*, UCSF, USA
  • Gastric Decompression, Steven Huang^, MD, The University of Texas MD Anderson Cancer Center, USA
  • Advanced Endoscopy Techniques, Jeffrey Chick*, MD, MPH, University of Washington, USA
12:00pm - 12:15pm

President's Closing Remarks

Location: Imperial A

SIO President, Matthew Callstrom*, MD, PhD, Mayo Clinic, USA